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Coexpression of cdk2/cdc2 and retinoblastoma gene products in colorectal
cancer
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Summan The retinoblastoma gene (Rb gene) is a tumour-suppressor gene and its product (pRB) is known to
act as a negative regulator of the cell cycle. Although lack of pRB expression resulting from gene alterations is
considered to be responsible for the genesis of several human malignancies. increased expression of pRB has
been demonstrated in a majon'ty ofcolorectal cancer cases. In the present study. we investigated the expression
of pRB as well as that of its related kinases, cdk2 and cdc2, in colorectal cancer, since these kinases have been
reported to phosphorylate and inactivate pRB. Western blot analysis revealed that colorectal cancer expressed
higher levels ofcdk2 and cdc2 than did normal mucosa and that the ratio of the hyperphosphorylated form of
pRB was higher in colorectal cancer. Furthermore, immunohistochemical studies showed that cdk2/cdc2 was
expressed exclusively in the cancer cells positive for pRB. These results suggest that an increase in the
expression of cdk2 cdc2 in colorectal cancer may have prevented pRB from braking the cell cycle through
phosphorylation.
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The Rb gene is the prototype for tumour-suppressor genes
whose biallelic inactivation is responsible for the development
of hereditary or sporadic retinoblastomas (Cavenee et al.,
1983; Murphree and Benedict. 1984). Loss of or structural
changes within the Rb gene have subsequently been demon-
strated in several other human malignancies, including
osteosarcomas (Fnrend et al.. 1986) and carcinomas of the
lung (Harbour et al.. 1988), breast (Lee et al., 1988) and
bladder (Horowitz et al.. 1989).
In contrast. colorectal cancer has reportedly shown infre-
quent inactivation of this gene (Vogelstein et al., 1989; Lothe
et al., 1992). and Southern blot analysis has demonstrated
Rb gene amplification in approximately 30% of colorectal
cancers (Gope et al.. 1990; Meling et al., 1991; Lothe et al..
1992). Northern blot and Western blot analyses have
revealed elevated expression of the Rb gene in more than half
of colorectal cancer cases (Gope et al., 1990; Gope and
Gope. 1992; Lothe et al., 1992).
The Rb gene encodes a nuclear protein of 110 kDa that
has multiple phosphorylation sites within the molecule (Lees
et al., 1991). The phosphorylation of pRB is considered to be
mediated by several kinases, so-called cdks (cyclin-dependent
kinases; Meyerson et al., 1992), which are activated at
specific points of the cell cycle. In normal cells, the under-
phosphorylated form of pRB is found in the Go and GI
phases of the cell cycle, while hyperphosphorylated pRB is
present in the S and G2 M phases (Buchkovich et al., 1989).
The underphosphorylated but not the hyperphosphorylated
form of pRB is known to be a target of various oncogenic
virus proteins such as SV40 large T, adenovirus EIA and
human papillomavirus E7 (Whyte et al., 1988; Dyson et al..
1989: Ludlow et al., 1989).
Furthermore, it has been demonstrated that the under-
phosphorylated form of pRB can form a complex with E2F
and inhibit its transcriptional activity (Hiebert et al.. 1992).
These data indicate that underphosphorylated pRB is an
active form which exhibits a growth-suppressive activity
(Chen et al., 1989; Mihara et al., 1989) and that the cdks
engaging in the phosphorylation of pRB are key enzymes
which control the cell cycle.
In higher eukaryotes, it has been suggested that a cycin-
dependent kinase 2 (cdk2; Fang and Newport, 1991; Tsai et
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al., 1993) phosphorylates pRB at the GI,S transition
(Akiyama et al., 1992; Kitagawa et al., 1992) and allows the
cells to enter the S phase, while another kinase, cdc2, par-
ticipates in pRB phosphorylation at G2/M (Lees et al., 1991;
Lin et al., 1991). In the present study, we investigated the
expression of cdk2/cdc2 in conjunction with that of pRB in
colorectal cancer. Analysis of the expression of these pRB-
related kinases is expected to afford an insight into the
significance of Rb gene overexpression in colorectal cancer.
Material and metbods
Antibodies
Anti-cdk21cdc2 monoclonal antibody SF6 (Yasui et al., 1993)
and anti-cdc2 specific monoclonal antibody 2A10 (Kitagawa
et al., 1992) were obtained from Medical and Biological
Laboratories (Nagoya, Japan). Both anitbodies were raised
against a synthetic peptide including the PSTAIRE motif
(Meyerson et al., 1992) common to both cdk2/cdc2 (amino
acid residues 30-57 of human p34"'), so that 5F6 recognises
both cdk2 and cdc2. whereas 2A10 reacts exclusively with
cdc2. Anti-cdk2 polyclonal antibody (Elledge et al., 1992)
was purchased from Upstate Biotechnology (Lake Placid,
NY, USA). This polyclonal antibody reacts specifically with
an epitope within the C-terminal domain (residues 287-298)
of human cdk2. Anti-pRB monoclonal antibody PMG3-245
(Jiang et al., 1993; Fukuda et al., 1994) was purchased from
Pharmingen (San Diego, CA, USA). This antibody reacts
with an epitope located between amino acids 300 and 380 of
authentic pRB.
Cell lines and tissues
Human colon cancer cell lines, SW480 and LoVo, were
obtained from the Japanese Cancer Research Resources
Bank. The cells were cultured in RPMI-1640 supplemented
with 10% fetal calf serum at 37C. Colonic tumours and
normal mucosa were obtained during surgery from 50
patients with colorectal cancer. We fixed one sample of
cancer tissue as well as its adjacent normal mucosa in
buffered formalin overnight for histological examinations and
it was dehydrated in graded ethanol at 4°C and embedded in
paraffin. From the other sample we collected tumour and
normal mucosa, excluding submucosa and propria muscle ascdk2/cdc2 and RB expressin in coecal cancer
H Yamanoto et al
much as possible for Western blotting. Tissues were
immediately frozen in liquid nitrogen and stored at -80°C.
Western blot analysis
About 2 x 10 cells in an exponential growth phase were
collected and lysed in 1.0 ml of lysis buffer [10 mM disodium
hydrogen phosphate. 154 mm sodium chloride, 1% Triton
X-100. 12 mM sodium deoxycholate, 3.5 mM so(dium dodecyl
sulphate (SDS). 0.2% sodium azide, 0.95 mM sodium
fluoride, 2mM phenylmethylsulphonyl fluoride (PMSF) in
1 M sodium dihydrogen phosphate pH 7.25 and 50 mg ml-'
aprotimnn and 50 mM leupeptin]. The lysates were clarified by
centrifugation at 14000g for 20mi at 4°C.
In ten cases of well or moderately differentiated tumours.
we analysed the expression of pRB and its related kinases,
cdk2 and cdc2, in cancer and normal tissue. We confirmed
histologically that these ten samples did not show significant
inflammatory involvement. Samples of 100 mg of tumour and
normal mucosa were homogenised in 1.0 ml of lysis buffer
and clarified by centrifugation at 15 000 g for 30 min at 4°C.
Total cellular protein was determined with the Bradford
protein assay (Bio-Rad, CA, USA) using bovine serum
albumin as a standard. Samples of 50 or 100 ig of protein
were treated with SDS-PAGE loading buffer (at a final
concentration of 65 mM Tris, 5% 2-mercaptoethanol. 3%
SDS and 10% glycerol) at 100°C for 5 min. The samples were
separated by electrophoresis on SDS-polyacrylamide gels
(12.5% for cdk2 or cdc2 and 7.5% for pRB) and transferred
to Immobilon polyvinylidene difluoride (PVDF) membranes
(Millipore. Bedford, MA. USA) in transfer buffer containing
192 mM glycine, 25 mm Tris pH 8.3, 20% (v/v) methanol and
0.02% SDS. After blocking with 5% skimmed milk, the
membranes were incubated with the primary antibody at the
following concentrations of the antibodies: PMG3-245,
lOgLgml-'; anti-cdk2, 2igm nil and 2A10, Sgigml-'. The
filters were washed with TBST [TBS (50 mM Tris-HCI
pH 7.5, 150 mM sodium chloride) plus 0.1% Tween20
(Sigma, St Louis, MO. USA)] followed by incubation with
alkaline phosphatase-conjugated second antibody. The filters
were washed in TBST and developed with the ProtoBlot
NBT and BCIP Color Development System (Promega.
Madison. WI. USA).
Densitometrn
Densitometric analysis of the Western blotting was per-
formed with Image Scanning (Molecular Dynamics, Sun-
nyvale, CA, USA). In ten cases of colorectal cancer, the
expression levels of cdk2, cdc2 and pRB were compared for
matched normal and cancer tissues. We further measured
both the total and hyperphosphorylated form of pRB in
matched pairs of normal and cancer tissue.
complexes were then washed off. and cdk cdc2 and pRB were
visualised by incubating the sections for 4 min in 0.05 M
Tris-HCl (pH 7.6) containing both 0.02% (w v) 3,3'-
diaminobenzidine tetrahydrochloride and 0.03% (v/v) hyd-
rogen peroxide.
A negative control section. to which normal mouse serum
had been applied. was included in each staining procedure. In
addition. the absorption test for 5F6 was carried out by
adding an excess amount of the synthetic peptides of cdk2
cdc2 used as immunogens.
Results
Western blotting
Differentiation between cdk2 and cdc2 expresssion by
Western blotting was obtained by using specific antibodies
for each kinase. Examination of ten matched pairs of normal
and cancer tissues revealed that colorectal cancer tissues
apparently expressed a higher level ofcdk2 and cdc2 than did
the corresponding normal mucosa (Figure la and b). Den-
sitometric analysis of the blotting membranes showed that
the amounts of cdk2 and cdc2 expressed in colorectal cancer
were respectively, 1.27-4.63 and 1.13-10.81 times those
expressed in normal mucosa (Table I).
Western blotting for pRB also revealed an increase in the
expression of normal-sized pRB in colorectal cancer tissues
(Figure 2). Densitometry showed that the total amount of
pRB with a molecular weight between 110 and 116 kDa in
cancer tissue was 0.74-4.06 times that in normal mucosa
(Table II), and the differential quantitation of pRB with a
molecular weight over 110 kDa (hyperphosphorylated form:
Ludlow et al.. 1989) revealed that the amount of the hyper-
phosphorylated form of pRB also increased in cancer tissues.
The ratio of hyperphosphorylated pRB to total pRB in the
cancer tissues was approximately 1-2.5 times that in normal
mucosa (Table II).
Immunohistochemistrv
Immunohistochemical staining with SF6 demonstrated that
cdk2 cdc2 was expressed in both normal and cancer tissues.
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Immunohistochemical staining
Serial sections of 4 gim thickness were prepared and analysed
for cdk2 cdc2 and pRB expression. The sections were first
deparaffinised in xylene and rehydrated with graded ethanol.
After quenching the endogenous peroxidase activity for
20 min in 0.1I% (w v) sodium azide containing 0.30% (v v)
hydrogen peroxide. non-specific binding was blocked by
treatment with 10% (v v) normal rabbit serum for 15 min.
Antibodies SF6 for cdk2 cdc2 and PMG3-245 for pRB were
applied to each section at a dilution of 1:100 and 1:50
respectively. and the sections were then incubated overnight
at 4'C in a moist chamber. After the sections had been
washed in 0.05 M phosphate buffer containing 0.145 M
sodium chloride pH 7.4 (PBS). biotinylated rabbit anti-mouse
immunoglobulin (HISTOFINE SAB-PO(M) Kit, Nichirei.
Tokyo. Japan) was applied, and the sections were incubated
for 20mmn at room temperature. This was followed by a
thorough washing in PBS. after which peroxidase-conjugated
streptavidin (HISTOFINE SAB-PO(M) Kit) was applied and
the sections were again incubated for 20 min. The excess
b
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Figure 1 Analysis of cdk2 and cdc2 in matched pairs of tumour
and normal colorectal tissues. (a) Western blotting of cdk2. Fifty
micrograms of cell lysate (LoVo) and the tissue extracts (N.
normal: T. tumour) was subjected to Western blotting using cdk2
polyclonal antibody. which reacts specifically with cdk2. Each
colorectal cancer tissue expresses a higher level of cdk2 than does
the corresponding normal mucosa. (b) Western blotting of cdc2.
The same lysates used in a were analysed using anti-cdc2
antibody 2A10. which reacts exclusively with cdc2. Colorectal
cancer tissues exhibit stronger bands for cdc2 than do normal
mucosae.
1232In normal epithelia. cdk2 cdc2 was expressed by a few
absorptive cells in the lower part of the glands (Figure 3a).
while cancer tissues contained various numbers of cdk2/cdc2-
positive cells (Figure 3b). The staining showed that cdk2/cdc2
was localised in both the nuclei and the cytoplasm, and the
validity of the staining was confirmed by the negative con-
trols immunostained with normal mouse serum or the preab-
sorbed antibody (Figure 3c).
Although the 50 cases of colorectal cancer tested always
included cells positive for cdk2/cdc2, the incidence of the
positive cells was different in each case. We therefore
classified the cancers into the following three groups: group a
(+ + +), >50% of the cells were positive for cdk2/cdc2;
group b (+ +). 10-50% of the cells were positive; and group
c (+). <10% of the cells were positive. Of the 50 cases
tested, 17 (34%) were classified into group a, 22 (44%) into
group b and 11 (22%) into group c. Fifty normal mucosal
Table I Colorectal tumour normal ratio' of cdks
No. c&-2 cdc2
1 2.17 1.13
2 1236 1.62
3 1.27 2.56
4 1.83 2.34
5 1.35 3.27
6 4.13 2.49
7 3.16 4.07
a 2.17 4.10
9 4.63 10.81
10 1.73 4.34
Median 2.17 2.92
'Theamount ofcdk2 orcdc2 in 50 iLgoflysatesfromcolorectalcancer
tissues compared with that from normal mucosa.
Table 11 Colorectal tumour normal ratio of pRB and percentage of
hyperphosphorylated pRB
HvperphosphorylatedpRBF (%)
No. T Na Normal (O% Tumour (0%)J T(%},N(%)
1 2.10 44 63 1.43
2 1.42 30 35 1.16
3 1.11 39 56 1.44
4 0.87 48 53 1.10
5 2.58 26 51 1.96
6 3.42 30 35 1.17
7 1.33 38 45 1.18
8 1.09 45 38 0.84
9 4.06 30 74 2.47
10 0.74 24 44 1.83
Median 1.38 34 48
3The amount ofpRB in 100 Lg oflysate from cancer tissue compared
with that from the corresponding normal mucosa. bHyperphosphory-
lated pRB as a percentage of total pRB.
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Fgwe 2 Western blotting of pRB in matched pairs of normal
and tumour colorectal tissues. One hundred micrograms of cell
lysate (SW480) and the tissue extracts (N, normal; T, tumour)
was subjected to Western blotting using anti-pRB antibody
PMG3-245. Colorectal cancer tissues represent a cluster of bands
around 110 116 kDa and show an increased expression of the
hyperphosphorylated form of pRB at more than 110 kDa. The
molecular weight of the underphosphorylated form of pRB is
indicated on the right (plORB).
Figwe 3 (a) Immunostaining of cdk2'cdc2 in normal colonic
mucosa using monoclonal antibody 5F6. A few absorptive cells
located at the lower part of the glands are positive for cdk2 cdc2.
Cdk2'cdc2-positive cells are indicated by arrows. (b) Immunos-
taining of cdk2/cdc2 in a case of colon cancer. Cancer cells
demonstrate cdk2/cdc2 in both the nuclei and the cytoplasm. (c)
An absorption test was carried out with 5F6 that had been
preabsorbed with an excess amount of the synthetic peptides of
cdk2/cdc2 used for immunisation. The absorbed antibody yields a
completely negative staining for cdk2/cdc2. Scale bars 200 Lm.
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staining patterns and clinicopathological
findings
Clinicopathological cdk2'cdc2 staining patterns (%)
parameters ++++ ++ +C Total
Dukes'
A. B 13 (41.9) 12 (38.7) 6 (19.4) 31
C 2 (16.7) 7 (58.3) 3 (25.0) 12
D 2 (28.6) 3 (42.8) 2 (28.6) 7
Tumour size (cm)
3.9> 7 (33.3) 9 (42.9) 5 (23.8) 21
4.0< 10 (34.5) 13 (44.8) 6 (20.7) 29
Depth of invasiond
m, sm 3 (23.1) 6 (46.2) 4 (30.8) 13
pm. s 14 (37.8) 16 (43.2) 7 (18.9) 37
Nodal involvement
13 (41.9) 12 (38.7) 6 (19.4) 31
+ 4 (21.0) 10 (52.6) 5 (26.3) 19
Liver metastasis
15 (34.9) 19 (44.2) 9 (20.9) 43
+ 2 (28.6) 3 (42.8) 2 (28.6) 7
Histological type
Well moderately 17 (36.9) 21 (45.7) 8 (17.4) 46
Poorly 0 1 (50.0) 1 (50.0) 2
Signet nrng cell 0 0 2 (100) 2
Total 17 (34.0) 22 (44.0) 11 (22.0) 50
a>50% of the cancer cells positive for cdk2/cdc2. b10-50% of the
cells positive. c<I0% ofthe cells positive. dm, mucosa; sin, submucosa;
p, propria muscle; s, serosa.
samples corresponding to each cancer tissue exhibited a low
level of expression of cdk2/cdc2, and they were all classified
into group c. Thus, the immunohistochemical data showed
that cdk2/cdc2 was overexpressed by 39 cases (78%) of the
tested colon cancers.
When the relationship between the incidence of cdk.2/cdc2-
positive cells and clinicopathological parameters such as
tumour size, depth of invasion, metastasis and histological
type was investigated, no significant correlation was
obtained, but it was found that well-differentiated and
moderately differentiated adenocarcinomas, which is the
major histological type of colon cancer, exhibited a high
incidence of cdk2/cdc2 expression. These findings are sum-
marised in Table III.
We then performed immunohistochemical staining of pRB
in the sections adjacent to those stained for cdk2/cdc2. The
Table IV Correlation between cdk2 cdc2 and pRB expression in
colorectal cancer
pRB
cdk2cdc2 NO. +++a + + +
+++ 17 17 0 0
++ 22 0 22 0
+ 11 0 0 11
Total 50 17 22 11
'>50% of the cancer cells positive. b10 of the cells positive.
c< 10% of the cells positive.
la lb
Ila llb
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Fgwe 4 A comparative immunohistochemical examination of cdk2/cdc2 and pRB in two cases of colorectal cancer (case I and
case II). cdk2 lcdc2-positive cancer cells coexpress pRB; cdk2/cdc2 is immunostained in la and Ia and pRB is shown in 1b and JIb.
Scale bar: Ia and b = 200pgm; Ila and b =lOOpm.
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Table III cdk2 cdc2cdk2/cdc2 and RB eipression in coorectal cancer
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immunoreactivity for pRB was found to be localised exclus-
ively in the nucleus of cancer cells, as reported previously
(All et al.. 1993: Fukuda et al., 1994); pRB-positive cases
were classified according to the same criteria as for cdk2
cdc2. Examination of 50 cases of colorectal cancer revealed
that there was a significant correlation between the incidences
of pRB and cdk2/cdc2 expression (Table IV). Furthermore.
comparative microscopic examinations of cdk2/cdc2 and
pRB in each case showed that pRB-positive cells coexpressed
cdk2/cdc2 (Figure 4).
Discussion
It has been suggested that pRB regulates the cell cycle by
restricting DNA replication (Goodrich et al.. 1991), while
cdk2 and cdc2 are known as kinases which form complexes
with cyclins (Sherr. 1993) and accommodate the function of
pRB through cell cycle-dependent phosphorylation. Among
the higher eukaryotes. cdk2 is considered to be one of the
key enzymes which phosphorylate and inactivate pRB at the
G1 S transition and allow the cells to enter S-phase (Akiyama
et al., 1992; Kitagawa et al.. 1992). while cdc2 does so at the
G2!M transition (Lees et al.. 1991: Lin et al.. 1991). Although
overexpression of cdc2 in colon cancer has been reported
previously (Yasui et al.. 1993). the distinction between cdk2
and cdc2 expression in colorectal cancer was made for the
first time in the present study. The result of Western blotting
clearly showed that the amount ofcdk2, which plays quite an
important role in the progression of cells into S-phase, in
colon cancer was as much as 1.3-4.6 times that in normal
mucosa. Cdk2 overexpressed in colorectal cancer may phos-
phorylate pRB and permit more cancer cells to enter S-phase,
while an excess amount of cdc2 may assist cell cycle progres-
sion through mitosis.
To identify cells producing cdk2 and cdc2. we performed
an immunohistochemical assay using SF6 monoclonal
antibody reactive with both kinases because 2A10 antibody
to cdc2 and anti-cdk2 antiserum were not available for
immunostaining of the paraffin sections. Localisation of
cdk2zcdc2 in normal mucosa indicated that cdk2 cdc2 expres-
sion correlated well with the proliferative activity of the cell.
The positivity for cdk2 cdc2 dramatically increased in cancer
tissues. implying that the number of cells with a potential for
replication had increased. The clinicopathological survey of
the 50 cases of colorectal cancers showed that the incidence
of cdk2 cdc2 overexpression was high in well-differentiated or
moderately differentiated adenocarcinomas and was not
affected by tumour stage. size. depth of invasion or meta-
stasis. This appears to indicate that the change in cdk2 cdc2
expression is an early event in colorectal carcinogenesis. In
fact. in a recent study of focal cancer in adenoma. we found
that cdk2 cdc2 was overexpressed even in such an early
cancer (data not shown). Immunohistochemical staining for
pRB in the serial tissue sections showed that the distribution
patterns of cdk2 cdc2- and pRB-positive cells were almost
identical in both normal and cancer tissues and it was
confirmed that the majority of cells positive for cdk2,cdc2
overexpressed pRB. This finding strongly suggests that cdk2
cdc2 plays a role in the phosphorylation of pRB.
We also found that the hyperphosphorylated form of pRB
with a molecular weight over 110 kDa increased in colorectal
cancer. and densitometric analysis clearly showed that the
majority of cancer tissues had higher percentage of hyper-
phosphorylated pRB than did normal mucosa. This result is
consistent with that reported previously by Gope and Gope
(1992). Although the reason for pRB overexpresion in col-
orectal cancer still remains to be clarified, a decrease in the
percentage of the underphosphorylated form of pRB
indicates that pRB overexpressed in cancer cells may not
effectively inhibit the cell cycle progression.
This study using Western blotting and immunohis-
tochemistry has demonstrated that overexpression of cdk2
cdc2 in colorectal cancer correlates well with an increase in
the percentage of hyperphosphorylated pRB. Concerning the
cell cycle regulation. however, further investigation is needed
because it has recently been reported that another kinase
namely cdk4 (Kato et al.. 1993). and cellular inhibitors of
cdks. including p21 (Xiong et al., 1993) and p16 (Serrano et
al., 1993). participate in the process of pRB phosphorylation.
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